Skip to main content

Advertisement

Table 1 Demographic and baseline characteristics of 138 patients with metastatic breast cancer

From: Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer

Characteristic HT group (n = 59) MCT group (n = 79) P value
Age (years)a    0.009 (t test)
Median 49 50  
 Range 37–76 34–66  
KPS score    0.349
 90–100 46 (78.0) 56 (70.9)  
 70–80 13 (22.0) 23 (29.1)  
Menopausal status    0.520
 Premenopausal 20 (33.9) 31 (39.2)  
 Postmenopausal 39 (66.1) 48 (60.8)  
HR status    
 ER-positive 55 (93.2) 73 (92.4) 0.855
 PgR-positive 51 (86.4) 65 (82.2) 0.509
Adjuvant HT    0.246
 Yes 50 (84.7) 72 (91.1)  
 No 9 (15.3) 7 (8.9)  
DFS (years)    0.446
 <2 16 (27.1) 17 (21.5)  
 ≥2 43 (72.9) 62 (78.5)  
 Mediana (months) 44 42 0.178 (t test)
No. of metastases    0.006
 <2 30 (50.9) 22 (27.9)  
 ≥2 29 (49.1) 57 (72.1)  
Metastatic sites    0.168
 Viscera 32 (54.2) 52 (65.8)  
 Non-viscera 27 (45.8) 27 (34.2)  
Prior adjuvant CT    
 Anthracycline 54 (91.5) 70 (88.6) 0.749
 Taxanes 32 (54.2) 53 (67.1) 0.170
Response to FCCT    0.009
 CR + PR 28 (47.4) 55 (69.6)  
 SD 31 (52.3) 24 (30.4)  
  1. HT hormonal therapy, MCT maintenance capecitabine monotherapy, KPS Karnofsky performance status, HR hormone receptor, ER estrogen receptor, PgR progesterone receptor, DFS disease-free survival, CT chemotherapy, FCCT first-line capecitabine-based combination chemotherapy, CR complete response, PR partial response, SD stable disease
  2. aExcept for these values, others are presented as the numbers of patients followed by the percentages in the parentheses